Compare HYPR & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | OKYO |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 71.4M |
| IPO Year | 2021 | 2021 |
| Metric | HYPR | OKYO |
|---|---|---|
| Price | $0.86 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.03 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 875.4K | 67.3K |
| Earning Date | 11-09-2026 | 07-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $49.18 | N/A |
| Revenue Next Year | $29.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.75 | $1.26 |
| 52 Week High | $2.22 | $3.20 |
| Indicator | HYPR | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 50.98 |
| Support Level | $0.75 | $1.29 |
| Resistance Level | $1.39 | $1.72 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 35.68 | 62.29 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.